Clinical trial
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
NCT00380068 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00380068 |
|---|---|
| Title | Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension |
| Official title | ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Hypertension |
| Intervention type | Drug |
| Interventions | Ambrisentan |
| Enrollment | 224 |
| Start date | Aug 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Sep 25, 2006 |
| Last update posted | Apr 5, 2012 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: